Cannabis Sativa Valuation

Is CBDS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBDS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CBDS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CBDS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBDS?

Key metric: As CBDS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CBDS. This is calculated by dividing CBDS's market cap by their current revenue.
What is CBDS's PS Ratio?
PS Ratio	3.2x
Sales	US$964.79k
Market Cap	US$2.08m

CBDS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	-4.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CBDS's PS Ratio compare to its peers?

The above table shows the PS ratio for CBDS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.04x
NVOS Novo Integrated Sciences	0.07x	n/a	US$990.8k
CNTG.F Centogene	0.04x	n/a	US$2.8m
GBNH.F Greenbrook TMS	0.02x	n/a	US$3.2m
CLRD Clearday	0.02x	n/a	US$298.8k
CBDS Cannabis Sativa	3.2x	n/a	US$2.1m

Price-To-Sales vs Peers: CBDS is expensive based on its Price-To-Sales Ratio (3.2x) compared to the peer average (0x).

Price to Sales Ratio vs Industry

How does CBDS's PS Ratio compare vs other companies in the US Healthcare Industry?

36 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$78.29b
CVS CVS Health	0.2x	4.5%	US$75.61b
COR Cencora	0.2x	6.5%	US$47.87b
CNC Centene	0.2x	5.5%	US$31.01b

36 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CBDS is expensive based on its Price-To-Sales Ratio (3.2x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is CBDS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBDS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CBDS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$89.53

12.7%

29.8%

Elevance Health

US$94.5b

Operates as a health benefits company in the United States.

ELV

US$401.96

2.0%

-15.5%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

3.8%

-17.8%